Aug 2026· Cell Reports Medicine· Vol 7, pp. 102918· 0 citations· 15 references
Medicine
TL;DR
Although GLP-1 receptor agonists show strong mechanistic rationale and supportive epidemiological signals for neuroprotection, large randomized trials in symptomatic AD have yielded negative clinical outcomes and do not support the therapeutic use in AD.
Abstract
Alzheimer’s disease (AD) is a multifactorial disorder that requires combined therapeutic strategies beyond amyloid clearance. Although GLP-1 receptor agonists show strong mechanistic rationale and supportive epidemiological signals for neuroprotection, large randomized trials in symptomatic AD have yielded negative clinical outcomes and do not support the therapeutic use in AD.
GLP-1 RAs demonstrate promising neuroprotective properties in preclinical and observational studies, though a clinical dualism exists where motor benefits in PD appear highly dependent on formulation kinetics.
Paulina Orzechowska, Gabriela Budziszewska, Aneta Dziurdź et al.· Biuletyn Głównej Biblioteki...· 0 citations
The phase 3 EVOKE and EVOKE + trials of oral semaglutide in early Alzheimer's disease missed their primary endpoint and every cognitive or functional secondary endpoint. A recent article by Hölscher revisits extension-phase data and reports partial separation at later timepoints, attributing the failure to limited brai...
A. M. Pereira da Silva, Diogo Haddad Santos· Journal of Alzheimer's Disea...· 0 citations
: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and a growing public health concern. Its core pathological features include cerebral amyloid-β deposition and tau aggregation. mRNA translation is a tightly regulated process essential for gene expression and protein synthesis. It plays critical rol...
Ling Li, Fang-Yu Dai, Hai-Peng Liu et al.· Clinical Interventions in Ag...· 0 citations
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded beyond glycemic control to include cardiovascular and renal risk reduction, with recent approval for reducing major adverse cardiovascular events in individuals with obesity or overweight and established cardiovascular disease. Increasing attention has...
Michelle Raja, Khushvi R. Patel, Pranav Krish et al.· Journal of Community Hospita...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.